Angiogenesis is the formation of new microvessels from existing vascular beds. AngII, a downstream product of renin, has been shown to be essential mediator of skeletal muscle angiogenesis in Dahl Salt Sensitive (SS) and Sprague Dawley rats, C57BL/6 mice, and human endothelial cells
in vitro.
Using partial chromosome introgression from the Brown Norway (BN) rat into the SS rat we have created two congenic lines with small (<300 Kbp) BN substitutions that differ by 23 Kbp. The congenic regions define an angiogenesis locus that contains one gene,
Btg2
. Sanger sequencing revealed no sequence variants in exons of
Btg2
between the BN and SS strains. Angiogenesis was measured using an
in vivo
electrical stimulation model of one hindlimb, with the contralateral leg acting as the control, in males and females of both new congenic strains. Males from Btg2
BN
have angiogenesis (TA=20.0±4.5% increase in vessel density in stimulated leg relative to unstimulated leg, EDL=15.8±5.8%,) while Btg2
SS
males did not have angiogenesis (TA=5.1±2.2%, EDL=4.4±2.7%). Females of both strains had angiogenesis: Btg2
BN
(TA=15.8±4.3%, EDL=3.4%), Btg2
SS
(TA=14.5±2.0%, EDL=14.6±2.5%). Stimulation significantly increased
Btg2
expression in both males and females. Btg2
SS
males had a significantly greater increase in
Btg2
mRNA in the stimulated muscle relative to unstimulated than Btg2
BN
males (5.0±0.9 versus 2.1± 0.3), but there was no difference in stimulated females (Btg2
BN
2.5±0.2, Btg2
SS
3.2±1.5). To test the hypothesis that
Btg2
impacted renin expression, we cloned the renin proximal promoter into a vector to drive luciferase, and co-transfected HEK-293 cells with this and vector(s) expressing
Btg2
or
Hoxb9
and
Btg2
. Normalized luciferase activity was 4.52±0.30 (arbitrary units) with an empty vector control and suppressed with the
Btg2
vector to 1.45±0.07. Co-expression of
Btg2
and
Hoxb9
lead to a further reduction in luciferase activity to 0.40±0.04. These data suggest the elevated
Btg2
expression observed in Btg2
SS
strain may be acting to suppress renin expression through renin proximal promoter transcription factor
Hoxb9
, leading to an inhibited angiogenic response.